S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Eli Lilly and Stock Forecast, Price & News

+4.08 (+2.19 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $190.77
50-Day Range
MA: $163.51
52-Week Range
Now: $190.77
Volume6.51 million shs
Average Volume5.25 million shs
Market Capitalization$182.49 billion
P/E Ratio31.17
Dividend Yield1.59%
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and logo


Overall MarketRank

1.97 out of 5 stars

Medical Sector

31st out of 1,480 stocks

Pharmaceutical Preparations Industry

12th out of 612 stocks

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$22.32 billion
Cash Flow$8.12 per share
Book Value$2.81 per share


Net Income$8.32 billion


Market Cap$182.49 billion
Next Earnings Date1/29/2021 (Confirmed)
+4.08 (+2.19 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

How has Eli Lilly and's stock price been impacted by Coronavirus?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LLY stock has increased by 36.2% and is now trading at $190.77.
View which stocks have been most impacted by COVID-19

Is Eli Lilly and a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Eli Lilly and?

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Friday, January 29th 2021.
View our earnings forecast for Eli Lilly and

How can I listen to Eli Lilly and's earnings call?

Eli Lilly and will be holding an earnings conference call on Friday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings data on Sunday, November, 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.71 by $0.17. The firm earned $5.74 billion during the quarter, compared to analysts' expectations of $5.87 billion. Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business earned $1.48 earnings per share.
View Eli Lilly and's earnings history

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, December 14th. Investors of record on Friday, February 12th will be given a dividend of $0.85 per share on Wednesday, March 10th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 1.78%. The ex-dividend date is Thursday, February 11th. This is a positive change from Eli Lilly and's previous quarterly dividend of $0.74.
View Eli Lilly and's dividend history

Is Eli Lilly and a good dividend stock?

Eli Lilly and pays an annual dividend of $2.96 per share and currently has a dividend yield of 1.59%. Eli Lilly and does not yet have a strock track record of dividend growth. The dividend payout ratio of Eli Lilly and is 49.01%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 37.09% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY21 earnings guidance on Tuesday, December, 15th. The company provided earnings per share (EPS) guidance of $7.75-8.40 for the period, compared to the Thomson Reuters consensus estimate of $8.00. The company issued revenue guidance of $26.5-28.0 billion, compared to the consensus revenue estimate of $26.39 billion.

What price target have analysts set for LLY?

15 analysts have issued 1 year price targets for Eli Lilly and's shares. Their forecasts range from $144.00 to $200.00. On average, they expect Eli Lilly and's share price to reach $172.21 in the next twelve months. This suggests that the stock has a possible downside of 9.7%.
View analysts' price targets for Eli Lilly and
or view Wall Street analyst' top-rated stocks.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a increase in short interest in December. As of December 31st, there was short interest totaling 6,890,000 shares, an increase of 24.1% from the December 15th total of 5,550,000 shares. Based on an average trading volume of 4,150,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.9% of the shares of the company are sold short.
View Eli Lilly and's Short Interest

Who are some of Eli Lilly and's key competitors?

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 53, Pay $4.4M)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 51, Pay $2.13M)
  • Dr. Daniel M. Skovronsky, Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs (Age 48, Pay $2.14M)
  • Mr. Jacob S. Van Naarden, Chief Operating Officer of Loxo Oncology (Age 36)
  • Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin.
  • Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 58)
  • Ms. Aarti Shreyas Shah Ph.D., Sr. VP & Chief Information and Digital Officer (Age 57)
  • Kevin Hern, VP of Investor Relations
  • Ms. Melissa Stapleton Barnes, Sr. VP of Enterprise Risk Management and Chief Ethics & Compliance Officer (Age 53)
  • Ms. Anat Hakim J.D., Sr. VP, Gen. Counsel & Sec. (Age 52)

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional investors include Atalanta Sosnoff Capital LLC (0.04%), Private Capital Advisors Inc. (0.04%), State of Alaska Department of Revenue (0.03%), Gateway Investment Advisers LLC (0.03%), Hexavest Inc. (0.02%) and Huntington National Bank (0.02%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, David A Ricks, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and

Which major investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Gateway Investment Advisers LLC, Atalanta Sosnoff Capital LLC, Fulton Breakefield Broenniman LLC, State of Alaska Department of Revenue, New England Research & Management Inc., Lavaca Capital LLC, and Sheets Smith Wealth Management. Company insiders that have sold Eli Lilly and company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill, and Stephen F Fry.
View insider buying and selling activity for Eli Lilly and
or view top insider-selling stocks.

Which major investors are buying Eli Lilly and stock?

LLY stock was purchased by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Private Capital Advisors Inc., Leelyn Smith LLC, IFM Investors Pty Ltd, Louisiana State Employees Retirement System, Strategic Investment Advisors MI, Strategic Wealth Designers, and Oak Harvest Investment Services. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and
or or view top insider-buying stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $190.77.

How big of a company is Eli Lilly and?

Eli Lilly and has a market capitalization of $182.49 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly and employs 35,065 workers across the globe.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.